Bessemer Group’s Maze Therapeutics MAZE Stock Holding History
Bought
Maintained
Sold
Other funds holding MAZE
Bessemer Group's MAZE Position: Q3 2026 in Review
Bessemer Group increased its Maze Therapeutics (MAZE) stake by 3% in Q3 2026, buying an estimated $401K and bringing the position to 496,253 shares worth $13.5M. The position accounts for 0.02% of the portfolio, ranked #347.
Bessemer Group first reported a position in MAZE in Q1 2025 and has held it in 7 quarters since. The position peaked at $20M in Q4 2025. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.
- Bessemer Group held 496,253 shares of Maze Therapeutics worth $13.5M as of Q3 2026.
- Bessemer Group bought 14,463 Maze Therapeutics shares in Q3 2026, an estimated $401K.
- Maze Therapeutics made up 0.02% of Bessemer Group's portfolio in Q3 2026, its #347 holding.
- Bessemer Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Bessemer Group's Maze Therapeutics position peaked at $20M in Q4 2025.
- 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.
Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.